The development of clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein 9 (Cas9) into therapeutic modalities requires the avoidance of its potentially deleterious off-target effects. Several methods have been devised to reduce such effects. Here, we present an Escherichia coli-based directed evolution method called Sniper-screen to obtain a Cas9 variant with optimized specificity and retained on-target activity, called Sniper-Cas9. Using Sniper-screen, positive and negative selection can be performed simultaneously. The screen can also be repeated with other single-guide RNA (sgRNA) sequences to enrich for the true positive hits. By using the CMV-PltetO1 dual promoter to express Cas9 variants, the performance of the pooled library can be quickly checked in mammalian cells. Methods to increase the specificity of Sniper-Cas9 are also described. First, the use of truncated sgRNAs has previously been shown to increase Cas9 specificity. Unlike other engineered Cas9s, Sniper-Cas9 retains a wild-type (WT) level of on-target activity when combined with truncated sgRNAs. Second, the delivery of Sniper-Cas9 in a ribonucleoprotein (RNP) format instead of a plasmid format is possible without affecting its on-target activity.
Introduction
In this paper, we aim to improve the specificity of Cas9 by combining different strategies. Various methods of avoiding the off-target effects of CRISPR-Cas9 have been developed. For example, truncated sgRNAs can be used to achieve higher specificity 1 . Additionally, the method of Cas9 delivery can be changed from a plasmid format to an RNP format to obtain higher specificity 2 . Specific amino acid residues of the Streptococcus pyogenes Cas9 (SpCas9) protein have been modified according to the rational design described previously 3, 4, 5 . Alternatively, amino acid residues have been altered in a random manner and the Cas9 variants with the highest specificity were identified using either a yeast 6 or an E. coli 7, 8 screening system.
However, many groups have reported that Cas9 variants engineered using the design to debilitate the nonspecific interaction between Cas9 and the substrate exhibit low on-target activities 7, 8, 9, 10, 11, 12 . We developed an E. coli-based directed evolution system, Sniper-screen, to screen randomly mutagenized Cas9 variants. An E. coli screening system has advantages over a yeast system because of the faster doubling time and higher transformation efficiencies of E. coli.
Both negative and positive selection, based on three different plasmids and a gene of interest (GOI) integrated into the E. coli genome, are used in Sniper-screen. Cas9 variants are expressed under the CMV-PltetO1 dual-promoter system of a low-copy number plasmid so that candidates identified in E. coli can be tested in mammalian cells without the need for subcloning. The GOI is introduced into the E. coli genome using the Tn7 transposon system. The sgRNA plasmid, which contains a temperature-sensitive origin of replication, expresses an sgRNA targeting the GOI; however, the sgRNA and GOI sequences are not perfectly matched. A perfectly matched sgRNA target site exists on a third plasmid containing the ccdB gene, which encodes a lethal product that poisons gyrase. In this system, cells expressing Cas9 variants with high off-target activities are removed because double-strand breaks (DSBs) are introduced into the mismatched site located in the genomic DNA. On the other hand, cells expressing Cas9 variants with low on-target activities are also removed because of lethal ccdB gene expression. The expression level of the Cas9 variants can be changed by altering the concentration of anhydrotetracycline (ATC), which adjusts the selection force.
Positive and negative screening for evolving Cas9
1. Target selection and plasmid construction 1. Select a target sgRNA spacer sequence in the GOI. Substitute one or two residues in the random nucleotide to produce a mismatched sequence. NOTE: Human EMX1 target site 3 (GAGTCCGAGCAGAAGAAGAA with GGG PAM) was used in the Sniper-Cas9 case. Followings are the mismatched sequences used: GAGTCCGAGCAGAAagAGAA, GAacCCGAGCAGAAGAAGAA, GAGTCCGAGCAGAgGAAGAA, and GAGcCCGAGCAGAAGAAGAA. 2. Insert the mismatched sequence (see step 3.1.1) into the sgRNA plasmid using standard oligonucleotide (oligo) cloning procedures 7 .
3. Insert the mismatched sequence with a PAM at the 3' end into p11-lacY-wtx1 (Table of Materials Survival frequency = the number of colonies on a selective plate / (the number of colonies on a nonselective plate x 10) 6. Pool the colonies that survived on the selective plates from all three libraries. Incubate the surviving colonies in 250 mL of LB medium supplemented with 12.5 μg/mL chloramphenicol at 42 °C overnight. Isolate the screened Cas9 library DNA using a midiprep kit. NOTE: This step clears the sgRNA plasmid. 7. Repeat the screening process from steps 3.3.1-3.3.6 until the survival frequency reaches a plateau. Use 10 ng of the selected Cas9 plasmid for transformation and 10 ng/mL of ATC during recovery. Maintain the ATC concentration at 100 ng/mL for the selective condition.
4. Shuffling and the second screening 1. Shuffle the selected pooled variants using the following DNA-shuffling protocol. PCR amplify the Cas9 insert in the Cas9 plasmid using flanking primers, 150 nucleotides from the insert boundaries. Digest 2 μg of amplified PCR product with DNase I for 1 min at 37 °C. 2. Purify fragments 70-200 bp in length using 2% agarose gel electrophoresis. PCR amplify the purified fragments. Use the product as a template to PCR amplify the Cas9 insert with appropriate primers flanking Cas9. Use the final PCR product to construct a Cas9 library as described in step 2.1.4. 3. Prepare new Sniper-screening cells (see section 3.2) with another mismatched sgRNA plasmid (see step 3.1.1). Redo the screening process (sections 3.2-3.3) until the survival rate reaches a plateau. Use 10 ng of the selected Cas9 plasmid for transformation and 10 ng/mL ATC during recovery. Maintain the ATC concentration at 10 ng/mL for the selective condition. . This figure has been modified from Lee et al. 7 . Please click here to view a larger version of this figure. On-target and off-target activities of Sniper-Cas9 compared to WT-Cas9 obtained using sgRNAs with variable lengths targeting the FANCF01 and AAVS sites. Specificity ratios were determined by dividing indel frequencies at on-target sites by those at the respective off-target sites. sgRNAs with a matched guanine at the 5' terminus (GX18 or GX19) and those with a mismatched guanine (gX17, gX18, gX19, or gX20) are indicated. Specificity ratios were not calculated when the normalized on-target activities were <70% 7 . This figure has been modified from Lee et al. 7 . Please click here to view a larger version of this figure.
Discussion
For those who want to avoid cumbersome screening procedures to obtain Sniper-Cas9, the Sniper-Cas9 protein and the encoding plasmid are available. Using these materials, the optimum length of the sgRNA, that providing the highest specificity ratio, should be determined. In addition, delivery of Sniper-Cas9 and sgRNA in an RNP format is recommended because it usually results in a higher specificity ratio than delivery in a plasmid format. Unlike Sniper-Cas9, other engineered Cas9 variants are not compatible with truncated sgRNAs 6, 7 or delivery in RNP form 8 (with the exception of HiFi-Cas9).
For Sniper-screen, the selection of the mismatched sequence is the most important step. Selection of a mismatched sgRNA that is associated with low cleavage activity toward the GOI sequence should be avoided. If not, Cas9 variants with a WT level of specificity will not cleave the E. coli genomic DNA with the mismatched target site. This effect will result in a large number of background colonies, jeopardizing the whole screening procedure.
Because E. coli has a fast doubling time and high transformation efficiency compared to yeast, Sniper-screen is advantageous compared to yeast-based screening methods. Additionally, Sniper-screen should be more sensitive than other E. coli-based systems in which the mismatched site is carried on a plasmid: there is one copy of the genomic DNA and thus only one copy of the mismatched site in our system, but a large number of plasmids within a single E. coli cell.
The specificities of other DNA endonucleases that induce DSBs, such as SaCas9 or Cpf1s, could also be improved by using Sniper-screen.
Unfortunately, Sniper-screen cannot be used to increase the specificity of base editors directly, because base editors do not induce DSBs in the genomic DNA of E. coli. As base editors use the nickase or dead version of Cas9 in the core of their system, the specificities of base editors could be increased by using the hits obtained from Sniper-screen.
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